Literature DB >> 6487446

A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. The European Malignant Hyperpyrexia Group.

.   

Abstract

A European Malignant Hyperpyrexia Group has been formed to facilitate exchange of information between centres performing in vitro muscle testing for malignant hyperpyrexia susceptibility. Data have been collected according to a protocol agreed by the Group. Based on these results, test criteria have been established to allow the following diagnoses to be made: MH susceptible (MHS); MH normal (MHN) or MH equivocal (MHE). It is accepted that MHE classified patients will be under permanent review, pending the collection of further data.

Entities:  

Mesh：

Substances：

Year:  1984        PMID： 6487446     DOI： 10.1093/bja/56.11.1267

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN： 0007-0912            Impact factor:   9.166


  54 in total

Review 1.  Caffeine and excitation-contraction coupling in skeletal muscle: a stimulating story.

Authors:  A Herrmann-Frank; H C Lüttgau; D G Stephenson
Journal:  J Muscle Res Cell Motil       Date:  1999-02       Impact factor: 2.698

2.  Identification and functional characterization of malignant hyperthermia mutation T1354S in the outer pore of the Cavalpha1S-subunit.

Authors:  Antonella Pirone; Johann Schredelseker; Petronel Tuluc; Elvira Gravino; Giuliana Fortunato; Bernhard E Flucher; Antonella Carsana; Francesco Salvatore; Manfred Grabner
Journal:  Am J Physiol Cell Physiol       Date:  2010-09-22       Impact factor: 4.249

3.  Bayesian modeling to predict malignant hyperthermia susceptibility and pathogenicity of RYR1, CACNA1S and STAC3 variants.

Authors:  Senthilkumar Sadhasivam; Barbara W Brandom; Richard A Henker; John J McAuliffe
Journal:  Pharmacogenomics       Date:  2019-09       Impact factor: 2.533

Review 4.  Fever after maxillofacial surgery: a critical review.

Authors:  Amelia Christabel; Ravi Sharma; R Manikandhan; P Anantanarayanan; N Elavazhagan; Pramod Subash
Journal:  J Maxillofac Oral Surg       Date:  2014-01-14

Review 5.  [Malignant hyperthermia].

Authors:  T Metterlein; F Schuster; B M Graf; M Anetseder
Journal:  Anaesthesist       Date:  2014-12       Impact factor: 1.041

6.  Genetic epidemiology of malignant hyperthermia in the UK.

Authors:  D M Miller; C Daly; E M Aboelsaod; L Gardner; S J Hobson; K Riasat; S Shepherd; R L Robinson; J G Bilmen; P K Gupta; M-A Shaw; P M Hopkins
Journal:  Br J Anaesth       Date:  2018-08-17       Impact factor: 9.166

7.  Anesthetic- and heat-induced sudden death in calsequestrin-1-knockout mice.

Authors:  Marco Dainese; Marco Quarta; Alla D Lyfenko; Cecilia Paolini; Marta Canato; Carlo Reggiani; Robert T Dirksen; Feliciano Protasi
Journal:  FASEB J       Date:  2009-02-23       Impact factor: 5.191

8.  [In-vivo diagnosis of malignant hyperthermia susceptibility: a microdialysis study].

Authors:  F Schuster; M Hager; T Metterlein; R M Muellenbach; T Wurmb; C Wunder; N Roewer; M Anetseder
Journal:  Anaesthesist       Date:  2008-08       Impact factor: 1.041

9.  [Onset of a fulminant malignant hyperthermia crisis. Case report of a 74-year-old patient with previously subclinical central core disease].

Authors:  M Wejbora; H Bornemann-Cimenti; D Lessel; C Mandl; H Voit-Augustin; G Schwarz
Journal:  Anaesthesist       Date:  2012-12-19       Impact factor: 1.041

10.  Allele-specific differences in ryanodine receptor 1 mRNA expression levels may contribute to phenotypic variability in malignant hyperthermia.

Authors:  Hilbert Grievink; Kathryn M Stowell
Journal:  Orphanet J Rare Dis       Date:  2010-05-19       Impact factor: 4.123
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.